Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study-Reference-Cited by-同舟云学术

Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study

Published:2019-09-25 Issue:6 Volume:14 Page:689-697
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Kim Jwa Hoon,Kim Sun Young,Kim Kyu-pyo,Kim Tae Won,Chae Sun Young,Kim Hwa Jung,Kim Jae Seung,Ryu Jin-Sook,Moon Dae Hyuk,Kim Jeong Eun,Hong Yong Sang

Funder

Asan Institute for Life Sciences, Asan Medical Center

Korea Health Industry Development Institute

Korea Foundation for Cancer Research

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s11523-019-00672-2.pdf

Reference23 articles.

1. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schutz G, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129:245–55.

2. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303–12.

3. Li J, Qin S, Xu R, Yau TC, Ma B, Pan H, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16:619–29.

4. Adenis A, de la Fouchardiere C, Paule B, Burtin P, Tougeron D, Wallet J, et al. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program. BMC Cancer. 2016;16:412.

5. Garcia-Alfonso P, Feliu J, Garcia-Carbonero R, Gravalos C, Guillen-Ponce C, Sastre J, et al. Is regorafenib providing clinically meaningful benefits to pretreated patients with metastatic colorectal cancer? Clin Transl Oncol. 2016;18:1072–81.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endocrine-related adverse conditions induced by tyrosine kinase inhibitors;Annales d'Endocrinologie;2023-05

2. What is thyroid function in your just-diagnosed cancer patient?;Frontiers in Endocrinology;2023-02-17

3. The Real-World Practice of Fruquintinib for Chinese Patients with Metastatic Colorectal Cancer;Cancer Management and Research;2021-08

4. Small bowel wall edema induced by regorafenib is associated with regorafenib intolerance and shorter survival in patients with metastatic colorectal cancer: A retrospective study;Journal of Oncology Pharmacy Practice;2020-12-06

5. Authors’ Reply to Yusuf Ziya Sener: “Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study”;Targeted Oncology;2020-05-27